Exponent (EXPO)
(Delayed Data from NSDQ)
$113.17 USD
-2.11 (-1.83%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $113.28 +0.11 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.17 USD
-2.11 (-1.83%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $113.28 +0.11 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Zacks News
New Strong Sell Stocks for March 4th
by Zacks Equity Research
AMED, CACC, and EXPO have been added to the Zacks Rank #5 (Strong Sell) List on March 4, 2022
Exponent (EXPO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 5.56% and 2.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exponent (EXPO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Franklin Covey (FC) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Franklin Covey (FC) delivered earnings and revenue surprises of 800% and 10.64%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Exponent (EXPO) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 15.00% and 3.83%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Exponent (EXPO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FTI Consulting (FCN) Appoints New Senior Managing Director
by Zacks Equity Research
FTI Consulting (FCN) welcomes Jim Wrynn to the position of senior managing director in its Global Insurance Services practice.
Exponent (EXPO): Strong Industry, Solid Earnings Estimate Revisions
by Aditi Saraogi
Exponent (EXPO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Are You Looking for a Top Momentum Pick? Why Exponent (EXPO) is a Great Choice
by Zacks Equity Research
Does Exponent (EXPO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Exponent (EXPO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 14.29% and 6.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Exponent (EXPO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tetra Tech (TTEK) Buys Kaizen, Expands International Footprint
by Zacks Equity Research
Tetra Tech's (TTEK) acquisition of Kaizen will enable it to boost its capabilities in international development management consulting services for its customers.
Exponent (EXPO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Exponent (EXPO) has been struggling lately, but the selling pressure may be coming to an end soon
Equifax (EFX) Rides on Product Strength, Debt Woes Stay
by Zacks Equity Research
Equifax (EFX) is benefiting from a solid product portfolio and clear understanding of the diverse sectors it serves.
Earnings Preview: Exponent (EXPO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exponent (EXPO) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 46.43% and 9.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exponent (EXPO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exponent (EXPO) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 25.93% and 4.57%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exponent (EXPO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Exponent (EXPO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exponent (EXPO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 40.91% and 3.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exponent (EXPO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Consulting Stocks That are Resilient to Coronavirus Mayhem
by Shuvra Shankar Dey
One of the earliest pioneers of remote working, the consulting services industry has been aiding industry players sail through the current turbulence.
Analysts Estimate Exponent (EXPO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exponent (EXPO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 11.36% and 0.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?